Ameriprise
SMMT icon

Ameriprise’s Summit Therapeutics SMMT Stock Holding History

Ameriprise’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$675K Sell
46,320
-1,347
-3% -$23.9K ﹤0.01% 3575
2026
Q1 		$904K Sell
47,667
-6,345
-12% -$103K ﹤0.01% 3341
2025
Q4 		$945K Buy
54,012
+500
+0.9% +$9.41K ﹤0.01% 3371
2025
Q3 		$1.11M Buy
53,512
+20,685
+63% +$502K ﹤0.01% 3315
2025
Q2 		$699K Sell
32,827
-9,543
-23% -$218K ﹤0.01% 3406
2025
Q1 		$817K Buy
42,370
+19,635
+86% +$394K ﹤0.01% 3288
2024
Q4 		$406K Buy
+22,735
New +$441K ﹤0.01% 3599

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Ameriprise's SMMT Position: Q2 2026 in Review

Ameriprise reduced its Summit Therapeutics (SMMT) stake by 2.8% in Q2 2026, selling an estimated $23.9K and leaving 46,320 shares worth $675K. The position accounts for ﹤0.01% of the portfolio, ranked #3575.

Ameriprise first reported a position in SMMT in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.11M in Q3 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Ameriprise held 46,320 shares of Summit Therapeutics worth $675K as of Q2 2026.
  • Ameriprise sold 1,347 Summit Therapeutics shares in Q2 2026, an estimated $23.9K.
  • Summit Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3575 holding.
  • Ameriprise first reported a position in Summit Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Ameriprise's Summit Therapeutics position peaked at $1.11M in Q3 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.